Newsroom
-
December 15 , 2023
Harbour BioMed's Wholly-owned Subsidiary Nona Biosciences Enters into a Global License Agreement with Pfizer for HBM9033, an MSLN-Targeted Antibody-Drug Conjugate (ADC)
Read more -
December 12 , 2023
SystImmune and Bristol Myers Squibb Announce a Global Strategic Collaboration Agreement for the Development and Commercialization of BL-B01D1
Read more -
December 6 , 2023
South Africa's Aspen expands reach with $100M buy of Sandoz's Chinese business
Read more -
December 1 , 2023
AbbVie to Acquire ImmunoGen, including its Flagship Cancer Therapy ELAHERE® (mirvetuximab soravtansine-gynx), Expanding Solid Tumor Portfolio
Read more -
November 29 , 2023
FDA Investigating Serious Risk of T-cell Malignancy Following BCMA-Directed or CD19-Directed Autologous Chimeric Antigen Receptor (CAR) T cell Immunotherapies
Read more -
November 24 , 2023
China's First NDA for a KRAS G12C Inhibitor: Innovent Announces the National Medical Products Administration of China Has Accepted and Granted Priority Review Designation to the New Drug Application for IBI351
Read more -
November 23 , 2023
Telitacicept (brand name: 泰愛®) formally granted full approval from conditional approval by NMPA for use in combination with conventional therapy in adult patients with active and auto-antibody positive systemic lupus erythematosus
Read more -
November 22 , 2023
Merck seals $610M biobucks deal to acquire preclinical neurodegenerative biotech Caraway
Read more -
November 21 , 2023
Bristol Myers Squibb and 2seventy bio Provide Update on U.S. FDA Review of sBLA for Abecma (idecabtagene vicleucel) in Earlier Lines of Therapy for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma
Read more -
November 20 , 2023
FDA signs off on new uses for Astellas and Pfizer's Xtandi, Merck's Keytruda
Read more -
November 18 , 2023
AstraZeneca's first-in-class FDA approval for Truqap marred by surprise restriction
Read more -
November 17 , 2023
BeiGene Receives European Commission Approval for BRUKINSA® (zanubrutinib) for the Treatment of Relapsed or Refractory Follicular Lymphoma
Read more